

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
6 June 2002 (06.06.2002)

PCT

(10) International Publication Number
WO 02/43769 A2

- (51) International Patent Classification⁷: A61K 47/48 (74) Agent: BOUVET, Philippe; Aventis Pharma S.A., Direction Brevets, 20 Avenue Raymond Aron, F-92165 Antony (FR).
- (21) International Application Number: PCT/EP01/13800
- (22) International Filing Date:
27 November 2001 (27.11.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/253,827 29 November 2000 (29.11.2000) US
0105346.1 5 March 2001 (05.03.2001) GB
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- (71) Applicant (*for all designated States except US*): AVENTIS PHARMACEUTICALS PRODUCTS INC. [US/US]; Route 202-206, P.O. BOX 6800, Bridgewater, NJ 08807-0800 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): HOFLAND, Hans [NL/US]; 126 Albacore Lane, Foster City, CA 94404 (US). LAMONS, Donald [US/US]; 125 Fox Crossing Court, Emerald Hills, CA 94062 (US). MENG, Xiao-Ying [CN/US]; 5317 Shamrock CM, Fremont, CA 94555 (US).
- Published:
— without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



WO 02/43769 A2

(54) Title: NEUTRAL AND ANIONIC COLLOIDAL PARTICLES FOR GENE DELIVERY

(57) Abstract: Processes for making neutral or anionic complexes containing sequestered DNA for gene transfer, by forming a stable colloid containing an aqueous phase having suspended therein a first DNA complex with a cationic surface potential comprising a DNA sequence complexed with a cationic lipid or polymer, and modifying the surface potential of the first DNA complex to form a stable colloid comprising a second DNA complex with a neutral or net anionic surface potential.

NEUTRAL AND ANIONIC COLLOIDAL PARTICLES FOR GENE DELIVERY

BACKGROUND OF THE INVENTION

5

1. Field of the invention

The invention provides methods and compositions for small, neutral or negatively charged colloidal structures that enable *in vivo* targeted DNA delivery to specific cell types.

10

2. Background information

Gene transfer vehicles, which have been successfully demonstrated to deliver exogenous genes *in vivo* can be divided into two major groups: the viral and the non-viral vectors, each with their own specific advantages and disadvantages. Non-viral carriers have gained recent attention because they offer attractive features that may overcome problems associated with use of viruses especially in the areas of production and immunogenicity. A wide variety of non-viral gene delivery systems have been described. Lipoplex, polyplex, or lipopolyplex have been described as the most efficient non-viral DNA delivery vehicles for systemic applications. Generally, these complexes contain cationic compounds (i.e. lipids or polymers) that are associated with the anionic DNA through electrostatic interactions, thus condensing and packaging the DNA in colloids that generally have an overall positive charge. The packaging of DNA into these complexes is very efficient. The particles provide protection for the DNA from degradation by nucleases on the one hand, while providing a means for cell uptake on the other. Cell uptake is mediated by binding of these cationic particles to the glycosaminoglycans (esp. heparan sulfates) on the cell surface. This determines the route of entry into the cell that ultimately leads to gene expression.

25

In addition to these advantages there are some issues associated with the use of non-viral vectors, mostly related to their relatively poor gene transfer *in vivo*. This lack of activity is due to the cationic nature of the system. After injection, the positive charge of the

CONFIRMATION COPY

complex causes the particles to bind anionic proteins present in the circulation. This causes the particles to be opsonized rapidly and subsequently scavenged by the reticulo endothelial system (RES). Recognition of bacterial DNA, especially the CpG motifs, by macrophages of the RES causes production of high levels of cytokines, such as IFN- γ , TNF- α , IL12, the major cause of acute toxicity which is dose limiting.

It would be advantageous to have the possibility to target gene delivery to specific cells. By redirecting the complex away from the RES and towards the target tissue, toxicity will be decreased while increasing efficacy. Unfortunately, the effect of targeting ligands is greatly overshadowed by this non-specific charge induced gene transfer process. In addition, when the positive charges are avoided, e.g. by using conventional liposomes, major problems in DNA packaging efficiency or colloid stability occur.

In the prior art polymers have been used to avoid RES uptake of liposomes. These polymers enable liposomes to circulate for prolonged periods of time and enable them to be targeted once a targeting ligand is conjugated to the end of the polymer chain. Various polymers have been used to sterically stabilize colloidal particles for *in vivo* use. A typical application is the attachment of polyethylene glycol (PEG) to the surface of liposomes using a lipid anchor (so-called "Stealth" technology)(See Lasic et al., Stealth Liposomes, CRC Press, 1995). This produces a hydrophilic layer on the surface of the liposome, which serves to physically block interactions with other surfaces, i.e. steric stabilization. This layer will reduce the zeta potential of the particle by physically moving the shear plane away from the surface. It does not, however, block the effect of the surface charge beyond the shear plane and out into the solution, as discussed in Fitch, Polymer Colloids, A Comprehensive Introduction, Section 7.4, Academic Press, 1997. Briefly: when ionized particles move in an electric field, they carry ions with them. The layer of carried ions adds to the hydrodynamic diameter of the particle and defines a new boundary called the shear plane. Past the shear plane, ions and solvent will not be carried by the particle. Elastic light scattering (ELS) can be used to measure the mobility of charged particles in an applied electric field and from that

the electrostatic potential (Ψ) at the shear plane is calculated. The magnitude of the electrostatic potential at the shear plane is called the zeta potential (ζ). Surface associated polymers (like PEG) physically control the movement of the solution near the surface and extend the effective shear plane. The zeta potential is reduced without affecting the electrostatic field. This effect is illustrated graphically in figures 1. and 2. The graph shows that steric interactions between particles are very strong, but are effective only close to the surface (dashed line). Electrostatic forces can extend beyond the range of typical surface associated polymers (solid line). That is, a neutral polymer attached at the surface of the particle provides a short-range barrier to collisions, but if the particle carries a strong surface charge, then the charge will be measurable beyond the extent of the surface attached polymer. Therefore, PEG attached to the surface of a cationic complex will only block some of the charge, and the complex will still be cationic to the solution (figure 2). Moreover, proteins in solution will continue to be attracted to the field that extends beyond the surface of the polymer, i.e. PEG containing particles will still be opsonized and removed by RES.

SUMMARY OF THE INVENTION

The present invention provides methods and compositions for efficient DNA packaging in neutral or negatively charged colloids. In addition, this invention enables targeted delivery of DNA to a specific site in the body after systemic administration.

Specifically, the present invention provides methods to reduce, eliminate or reverse the positive charge of particles obtained by complexation of a cationic component to the anionic DNA. The invention also contemplates the composition of the final colloid that enables targeted gene delivery. Preferred methods and compositions of the present invention provide advantages of efficient DNA packaging combined with particle stability in serum and targetability.

Therefore, according to one aspect of the present invention, a process for making neutral or anionic complexes containing sequestered DNA for gene transfer is provided, in

which a stable colloid is formed wherein the aqueous phase has suspended therein a first DNA complex with a cationic surface potential containing a DNA sequence complexed with a cationic lipid or polymer, after which the surface potential of the first DNA complex is modified to form a stable colloid containing a second DNA complex with a neutral or net anionic surface potential.

In one embodiment, plasmid DNA is associated with a polyvalent cationic lipid resulting in a stable colloid with a positive surface potential. Preferred lipids contain polyvalent cationic head groups such as linear polyamines (e.g. spermine, spermidine), branched polyamines (RPR209120 cf figure 4) or polyamines containing guanidinium groups (RPR204014 cf figure 7). In addition, preferred lipids contain hydrophobic moieties that are based on one or more acyl chains of various lengths such as meristyl or palmityl. This colloid is then modified by adding an agent that reacts with the positively charged amines of the cationic lipids, thus consuming the charge of the colloid. Two preferred chemical reagents are citraconic anhydride (CCA) and NHS-Acetate.

In another embodiment, the charge of the complex may be reduced to the point where the colloidal stability is affected. In this case a polymer, such as a poly(alkylene oxide), and in particular a polyethylene glycol (PEG), may be added to the solution or incorporated into the surface of the particles to replace electrostatic stabilization with steric stabilization.

In yet another embodiment, targeting ligands are added to the complex, either before or after charge modification. These targeting ligands provide an uptake mechanism that provides a route of entry into the cell and ultimately lead to gene expression. Preferred targeting ligands are folate (RPR258018 cf fig 13), or tumor homing peptides such as RGD or NGR.

In another application, the charge modification is reversible under acidic pH. Thus triggering the release of the modifying group and reconstituting the highly active cationic complex as is the case for CCA modified RPR204014/DNA complexes (fig 7).

The invention will be especially useful for systemic, targeted delivery of DNA. One preferred application is for the treatment of malignant tumors. Small neutral or anionic particles can exit the circulation and enter tumor tissues by means of the well-known enhanced permeation "leaky vasculature" and retention "no lymphatic drainage" (EPR) phenomenon associated with malignant tumors. Other particularly suitable tissues to target include sites of inflammation, liver and spleen. Particles, which are additionally equipped with surface associated ligands, can specifically transfect additional target tissues, such as proliferating endothelial cells.

Thus another object of the present invention is the use of a colloid according to the present invention for the preparation of a medicament comprising an exogenous therapeutic DNA sequence for treating by gene therapy a patient in need thereof.

Another object is the use of a colloid according to the present invention for the preparation of a medicament intended for the administration of an exogenous therapeutic DNA sequence.

A further object is a composition, and in particular a pharmaceutical composition, comprising a colloid according to the present invention.

Non-specific gene transfer and CpG mediated toxicity are the main causes of inefficiency of non-viral gene delivery systems to date. This current invention reduces both non-specific gene transfer and CpG mediated toxicity, enabling cell specific, receptor mediated gene transfer.

Attempts have been made to use neutral or anionic materials to package DNA. However, literature in the field clearly indicates that charge neutrality leads to major problems in packaging efficiency and/or colloid stability. The novelty of this invention lays in the fact that cationic lipids are used to package DNA in their highly effective manner first.

Subsequently, the cation is modified into a neutral or anionic compound while retaining DNA packaging and particle stability. Many of the polyvalent lipids with short acyl chains have been shown to give stable particles after chemical modification.

Stable colloids prepared by process of the invention and gene therapy techniques
5 utilizing the colloids are also disclosed. These and other features of the invention and the advantages thereof will become more fully apparent when the following detailed description of the invention is read in conjunction with the accompanying figures.

BRIEF DESCRIPTION OF THE DRAWINGS

10

Figure 1 is a graphical representation of repulsive force versus distance to next surface of like charge as applied to charged particles contained within a colloid. Based on Fitch, Polymer Colloids, A Comprehensive Introduction, Section 7.4, Academic Press, 1997.

Figure 2 is a graphical and pictorial representation of the variation in electrical
15 potential (Ψ) as a function of distance from the surface. When ionized particles move in an electric field, they carry ions with them. The layer of carried ions adds to the hydrodynamic diameter of the particle and moves the shear plane out away from the surface. Past the shear plane, ions and solvent will not be carried by the particle. Elastic light scattering can be used to measure the mobility of charged particles in an applied electric field and from that the
20 electrostatic potential (Ψ) at the shear plane is calculated. The magnitude of the electrostatic potential at the shear plane is called the zeta potential (ζ).

Figure 3 is a pictorial representation of charge fields at the surfaces of cationic complexes with and without modification with PEG₂₀₀₀ and/or chemical modification.
25 Surface associated polymers (like PEG₂₀₀₀) physically control the movement of the solution near the surface and extend the effective shear plane. The zeta potential is reduced without

affecting the electrostatic field. Chemical modification of the amines at the surface of the particles can be used to alter the electrostatic field around the particle.

Figure 4 is a representation of the chemical reaction of NHS-acetate with the amine
5 end group(s) of a typical cationic lipid (RPR209120).

Figure 5 is a graph showing the modification of zeta potential in a cationic lipid complex using NHS-acetate. The NHS active ester, NHS-acetate, will react with RPR209120 to acetylate primary amines and reduce the surface charge, shown here by a reduction of the zeta potential. Zeta potential determined using a Coulter DELSA 440 electrophoretic light
10 scattering (ELS) instrument.

Figure 6 is a graph showing the modification of zeta potential and comparing the reaction of NHS-acetate with different lipid complexes. Complexes with RPR209120 (primary amine) react readily with NHS acetate, where RPR204014 (guanidinium and secondary amines) will not. Using high concentrations of the active ester, the zeta potential
15 can be reduced to zero and even reversed.

Figure 7 is a representation of the reversible chemical reaction of citraconic acid anhydride with the amine end group of a typical cationic lipid.

Figure 8 is a composite graph showing biodistribution to all affected tissues using
20 NHS-acetate charge-modified particles made in accordance with Example 1.

Figure 9 is a composite graph showing biodistribution to all affected tissues using citraconic acid charge-modified particles made in accordance with Example 2

Figure 10 is a graph of the blood level at 0.5 and 6.0 hours of injected particles of NHS-acetate charge modified particles at different molar ratios of NHS-acetate to lipid.
25 Circulation in blood as a function of time following IV injection and the amount of active ester used to react the particles. (Biodistribution in the mouse is tracked using the gamma emitter, ¹¹¹Indium attached to the complex using a metal chelator-lipid conjugate. Complex is

administered by tail vein injection. Mice are pre-injected subcutaneously with cultured tumor cells, 4T1, 10 to 14 days prior to testing.)

Figure 11 is a graph of the percent of total dose in the spleen at 0.5 and 6.0 hours of injected particles of NHS-acetate charge modified particles at different molar ratios of NHS-acetate to lipid.

Figure 12 is a graph of the percent of total dose in a tumor at 0.5, 6.0 and 24 hours of injected particles of NHS-acetate charge modified particles at different molar ratios of NHS-acetate to lipid.

Figure 13 Folate mediated gene transfer in vitro of NHS-Acetate modified lipid DNA complex: 1 µg DNA + 5nmole RPR209120 + 1nmole RPR204014 + 0.3nmole RPR 204293 w/w 0.3nmole distearyl-PEG₅₀₀-Folate (RPR258010), which was inserted after the complex was formed.

Figure 14 Expression of CAT transgene in different organs after IV injection of 100, 200, 400 or 800 µg DNA in chemically modified particles. Data are mean and individual values of four animals.

DETAILED DESCRIPTION OF THE INVENTION

The invention provides methods and compositions for DNA packaging in small, neutral or negatively charged colloidal structures that enable *in vivo* targeted delivery to specific cell types. In accordance with the process of the present invention, complexes are formed comprising a core of plasmid DNA and cationic lipid. These complexes are initially in the form of fine particles suspended in an aqueous environment. The particles initially have a positive surface potential. The colloid is then modified by the addition of an agent that reacts with the positively charged groups of the cationic lipid to reduce, remove or reverse the charge at the surface or throughout the lipid complex. Modifying the charge of these lipid particles reduces their interactions with anionic proteins and cell surfaces to

which they are exposed, thus enabling targeted gene delivery.

Stable particles containing active plasmid DNA can be produced using a self-assembling process where cationic lipids or cationic lipid / neutral lipid mixtures are attached to DNA by ionic interactions. The lipids are first put in aqueous suspension as micelles or liposomes. As these particles bind to DNA, a spontaneous rearrangement produces sections of lipids in bilayers sandwiching the DNA. If enough lipid is used, all of the DNA becomes sequestered within the lipid structure and is unavailable to compounds in solution such as DNase. The particles can be subsequently used for *in vivo* gene therapy. However, strong positive charge of the particles causes serum proteins to bind, which in turn leads to opsinization and rapid scavenging by the RES system. Uptake and digestion by macrophages causes acute elevation of cytokines, such as IFN- γ , TNF- α or IL12, which leads to a dose limiting toxicity. The process of the present invention takes advantage of this self-assembling system to package the DNA, but adds a chemical modification of the lipids to reduce or reverse the zeta potential. The DNA remains in its convenient protective package, that is, enveloped in lipids. The result is that a cationic lipid is used to package DNA in a complex, which is subsequently altered to form a neutral or anionic colloid in which the DNA is still present. These modified particles have a decreased acute toxicity profile, and are now enabled for the use in targeting approaches by eliminating non-specific charge mediated gene transfer.

Cationic lipids suitable for use in such particles may have primary, secondary or guanidino amines as described, for example, in "Liposomes in Gene Delivery." D.D. Lasic (Ed.) CRC Press, Boca Raton (1997). Other cationic agents used to condense DNA could be used in this manner. Polymers such as polyethyleneimine, polylysine and dendrimers are examples.

The cationic lipid particles of the present invention may comprise cationic lipids in combination with neutral lipids. Neutral lipids suitable for use in forming the cationic lipid

particles include DOPE, DOPC, Cholesterol, RPR204293 as described, for example, in "Liposomes in Gene Delivery." D.D. Lasic (Ed.) CRC Press, Boca Raton (1997).

Obvious to one skilled in the art, the choice of solvent is irrelevant to this application.

One example of a class of compounds used to react with primary amines is NHS esters. An example of such an ester is the acetic acid derivative: N-hydroxysuccinimide acetate (NHS-acetate). NHS-acetate is a simple blocking reagent and the reaction product is not reversible. The chemical modification of a typical cationic lipid with NHS-acetate is illustrated in Figure 4. In this example the cationic lipid is RPR209120 (2-(3-[Bis-(3-amino-propyl)-amino]-propylamino)-N-ditetradecylcarbamoylethyl-acetamide), which has two primary amino groups. The reaction can be mono-substitution to reduce the positive charge or di-substitution to eliminate the positive charge, or a combination thereof to reduce the charge to an intermediate level. Figure 5 is a graph showing the modification of zeta potential in RPR209120/DNA/PEG₂₀₀₀ complex using NHS-acetate. The data is presented as the zeta potential (ELS) in mV as a function of the molar ratio (M/M) of active ester to total lipid. Figure 6 is a graph showing the effect on zeta potential for the reaction of NHS acetate with similar lipid/DNA/PEG₂₀₀₀ complexes using RPR209120 (primary amine) and RPR204014 (a guanidino amine, as shown in Figure 7). The NHS-acetate reacts readily with the primary amine, but is not as reactive with secondary and guanidino amines such as the RPR204014.

Another preferred class of compounds for use in the charge modification process of the present invention is anhydrides that are reactive with guanidino amine groups. An example of such an anhydride is citraconic acid anhydride (CCA). CCA is reactive with guanidino amines and its chemistry is reversible. The chemical modification of a typical cationic lipid with citraconic acid anhydride is illustrated in Figure 7. In this example the cationic lipid is RPR204014 (N-Ditetradecylcarbamoylethyl-2-{3-[4-(3-guanidino-propylamino)-butyl-amino]-propylamino}-acetamide that has a guanidino amine group. In this case the reaction blocks the amine and adds a carboxylic acid functional group. As also

shown in Figure 7, the reaction of citraconic acid anhydride is reversible at low pH, wherein citraconic acid is produced and the lipid returns to its positively charge amide form. This feature of reversibility of the reaction of citraconic acid anhydride at low pH adds a useful adjustability to this reaction.

5 In cases in which the charge is reduced to the point where the colloid stability is affected, a polymer or other agent may be added to the solution or incorporated into the surface of the particle to replace electrostatic colloid stabilization with steric stabilization.

The charge-modification process of the present invention can be applied to sterically protected (i.e. PEG-coated) particles to reduce the surface potential to zero or to even
10 produce anionic particles, as illustrated in Figure 2, and in greater detail in Figure 3.

Preferred conditions for these charge modification reactions are those allowing the reaction to take place under mild conditions as to not interfere with particle stability, and/or DNA integrity. More specifically conditions that cause aggregation of the cation/DNA complex should be avoided, i.e. conditions of high ionic strength (>150mM NaCl). In
15 addition, conditions should be avoided that could damage the DNA integrity, i.e. conditions of extremely high or low pH. Preferred reaction conditions take place in a pH range of 6-8. Also, reactions generating extreme heat should be avoided for the same reasons.

The process of the present invention is particularly useful for particles containing plasmid DNA. Oligonucleotides, RNA and small oligopeptides are also suitable for use in
20 this process. The main objective of the invention is for systemic, targeted delivery of these compounds *in vivo*. One preferred application is for the treatment of malignant tumors. Other particularly suitable tissues to target include sites of inflammation, liver and spleen. Particles, which are additionally equipped with surface associated ligands, can specifically transfect additional target tissues, such as proliferating endothelial cells, in the absence of
25 strong charge-charge interactions.

The following examples illustrate methods of preparation of charge modified lipid/DNA complexes, which provide efficient packaging of DNA, stable colloidal structures

with neutral or negative charge, that are targetable. The examples are intended only to illustrate specific compositions and methods of the invention, but are in no way intended to limit the scope thereof.

EXAMPLE 1

5 NHS-ACETATE MODIFIED COMPLEX

This example demonstrates the use of NHS-acetate to modify the surface charge of cationic lipid particles containing plasmid DNA. Cationic particles were made by first combining the cationic lipid RPR209120 (2-(3-[Bis-(3-amino-propyl)-amino]-propylamino)-N-ditetradecylcarbamoylmethyl-acetamide), a typical plasmid DNA and a conjugate of
10 polyethylene glycol and lipid (DSPE-PEG, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[poly(ethylene glycol) 2000]) (Avanti Polar Lipids, PN 880120). The resulting complex was then reacted with the active ester NHS-acetate.

The lipid components, RPR209120 and DSPE-PEG were combined in chloroform at a molar ratio of 10:1 (10% DSPE-PEG). The lipid components were deposited as a thin film
15 by evaporation of the organic solvent by rotating the solution under a stream of argon or under reduced pressure. The lipid component was further dried under vacuum (less than 0.10 mm Hg for four hours). 5% dextrose, 20 mM NaCl solution was then added to produce a lipid suspension with a concentration of 3 mM. This was incubated over night at 4°C and then sonicated to produce a uniform suspension of micelles. Equal volumes of this
20 suspension and a plasmid DNA solution (0.5 mg/ml in 5% dextrose, 20 mM NaCl) were quickly mixed to produce a stable colloid of lipid/DNA/PEG complex particles of 70 to 100 nm in diameter (ELS).

The colloidal suspension of lipid complex was then reacted with a freshly made aqueous solution of an active ester comprising acetic acid and N-hydroxysulfosuccinimide
25 ester (NHS-acetate) at room temperature for one hour and then dialyzed over night at 4°C against 5% dextrose, 20 mM NaCl. The reaction chemistry is illustrated in Figure 1. The amount of NHS-acetate active ester can be varied from about one-tenth to about ten times

molar ratio to total lipid to produce particles with reduced to no surface charge. Higher ratios of NHS-acetate active ester to total lipid have produced negatively charged particles.

The attached graphs (Figures 5 and 6), show the relationship of the amount of NHS-acetate active ester to the resulting zeta potential (ELS) in mV. Particle size by dynamic light scattering analysis increases slightly with the amount of reaction as does the fluorescence signal of ethidium bromide (EB) staining (Table 1). However, DNA was found to be still packaged in the lipid particles, as determined by its retardation during agarose gel electrophoresis.

TABLE 1

mole ratio	zeta potential	EB	Size
0	16.42	4.6	131
1:1	-2.19	5.7	151
5:1	-0.36	10.2	168
10:1	-2.09	11.0	169
50:1	-15.0	13.1	189

EXAMPLE 2

CITRACONIC ACID ANHYDRIDE MODIFIED COMPLEX

Cationic lipid particles consisting of RPR204014 (N-Ditetradecylcarbamoylmethyl-2-{3-[4-(3-guanidino-propylamino)-butylamino]-propylamino}-acetamide and DNA with a ratio of one μ g of DNA per 6 nmol of RPR204014 lipid were 60 to 80 nm in diameter with a zeta potential of about 40 mV. Reacting these particles in carbonate buffer, pH 9, with 4 mM citraconic acid anhydride [CAS 616-02-4] (CCA) resulted in stable particles with a zeta

potential of about -40 mV. At a lower pH of 5.5 the reaction reverses reverting the particle to cationic. The chemistry of this reaction is illustrated in Figure 7.

Table 2 presents the zeta potential before and after CCA modification at pH 5.5 for two hours at room temperature (RT).

5

TABLE 2

CCA/lipid Ratio	Zeta Potential before incubation (mV)	Zeta Potential after incubation at pH 5.5 for 2 hr at RT (mV)
0	11.4	20.74
6	9.75	12.24
10	0.68	5.6
50	-6.17	7.63
100	-10.0	8.74

10

EXAMPLE 3

BIODISTRIBUTION STUDIES

As discussed above, the present process modifies cationic particles to reduce the difference in surface charge between them and the *in vivo* environment. This reduces the amount of product that is captured onto blood cells and other anionic tissue membranes. Opsonizing proteins may also be inhibited from binding. These particles, being small enough, can then enter certain tissues through openings in the capillary walls, either through fenestrae (as in the liver) or through "leaky vasculature" associated with cancer tumors or

15

inflamed tissues. Such charge-modified particles can then react with cells through weak ionic or entropic processes. Target tissues include sites of inflammation, cancer tumors, tumor endothelium, and liver. Biodistribution in a mouse was tracked using the gamma emitter $^{111}\text{Indium}$ attached to the complex using a metal chelator-lipid conjugate. The complex was administered by tail vein injection. Mice were pre-injected subcutaneously with cultured tumor cells (4T1) 10 to 14 days prior to testing. The results are set forth as % of injected dose in blood versus molar ratio of NHS-acetate to total lipid, with data shown for circulation times of 30 minutes (squares) and 6 hours (triangles).

The biodistribution of these particles was measurably different from unmodified particles in circulation time, tumor uptake and affect on spleen. Figure 8 is a composite graph showing biodistribution to all affected tissues of NHS-acetate charge-modified particles made in accordance with the process of Example 1. Figure 9 is a composite graph showing biodistribution to all affected tissues of citraconic acid charge-modified particles made in accordance with the process of Example 2.

Figure 10 is a graph of the blood level at 0.5 and 6.0 hours of injected particles of NHS-acetate charge modified particles at different molar ratios of NHS-acetate to lipid. As illustrated in Figure 10, blood levels were significantly higher for modified particles at both 0.5 and 6 hours. Figure 10 shows circulation in blood as a function of the degree of modification by NHS-acetate. The data present the time following IV injection of NHS-acetate charge-modified particles made in accordance with the process of Example 1, and the amount of active ester used to react the particles.

Injected particles should not interact with circulating blood cells. Longer circulation times at 0.5 and 6 hours could be a result of reduced particle adsorption to blood cells. Red blood cells damaged by particles would be expected to end up in the spleen. Figure 11 presents data, which demonstrate that charge-modified particles have a lower impact on the spleen. The data is set forth as the % of total dose in spleen versus the molar ratio of active ester to total lipid, with data shown for circulation times of 30 minutes (squares) and 6 hours

(triangles). Data for the spleen show that with charge modified particles made in accordance with the process of Example 1, less of the trace goes to the spleen.

Figure 12 shows an enhanced uptake in a tumor of the NHS-acetate modified complex particles of Example 1. The data is set forth as the % of total dose in the tumor versus molar ratio of active ester to total lipid, with data shown for circulation times of 30 minutes (circles), 6 hours (triangles) and 24 hours (squares). About 50% more charge modified complex (5 and 10 molar excess of NHS-acetate) ends up in the tumor after both 6 and 24 hours.

10 EXAMPLE 4 : TARGETED GENE TRANSFER IN VITRO

In the absence of strong charge-charge interactions particles which are additionally equipped with surface associated ligands can react with additional targeted tissues, i.e. with cells having binding sites for the specific ligand. The particles contain plasmid DNA which when transfected to the target cells will produce the therapeutic agent over an extended period of time. Folate mediated gene transfer in vitro of NHS-Acetate modified lipid DNA complex was investigated using M109 cells in vitro. The following formulation was used 1 μ g DNA + 5nmole RPR209120 + 1nmole RPR204014 + 0.3nmole RPR 204293 w/wo 0.3nmole distearyl-PEG₄₀₀-Folate (RPR258018), which was inserted after the complex was formed. The rationale behind this formulation was: RPR209120 will be modified by NHS-Acetate; RPR204014 will not be modified, i.e. will help stability of the particle, since PEG lipids cannot be used (shielding of targeting ligand containing only short PEG linker); RPR204293 is a neutral helper lipid which will help stabilize the complex and help endosome escape; RPR258018 has been shown to specifically bind to folate receptor on M109 cells. Free Folate (FF) was used to compete with the particles, i.e. to show folate mediated gene transfer. The results are shown in figure 13. High nonspecific (not competed with FF) gene transfer was found for non-modified cationic complex with or without RPR258018. Modification of the complex with 5 fold molar excess of NHS-Acetate (vs

RPR209120 amines) resulted in a 100-fold reduction in gene transfer. The reduction in gene transfer could be partially (10 fold) restored by addition of the targeting lipid RPR258018. RPR258018 mediated gene transfer of 5Ac-modified complex could be competed with free folate, suggesting receptor mediated gene transfer.

5

EXAMPLE 5: GENE TRANSFER IN VIVO

This example illustrates the use of particles modified with NHS-acetate for in vivo gene transfer. Cationic particles are made by first combining the cationic lipid RPR209120 (2-(3-[Bis-(3-amino-propyl)-amino]-propylamino)-N-ditetradecylcarbamoylmethyl-acetamide), neutral lipid DOPE (dioleoyl-phosphatidylethanolamine), a conjugate of polyethylene glycol and lipid (DSPE-PEG, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[poly(ethylene glycol) 2000]) and plasmid DNA encoding chloramphenicol acetyl transferase gene (CAT). The resultant complex is then reacted with the active ester NHS-acetate.

The lipid components, RPR209120, DOPE and DSPE-PEG are combined in chloroform at a molar ratio of 10:10:0.8. The lipid components are deposited as a thin film by evaporation of the organic solvent by rotating the solution under a stream of argon or under reduced pressure. The lipid component is further dried under vacuum (less than 0.10 mm Hg for four hours). 5% dextrose, 20 mM NaCl solution is then added to produce a lipid suspension which is sonicated to produce a uniform suspension of liposomes. Equal volumes of this suspension and a plasmid DNA solution (0.5 mg/ml in 5% dextrose, 20 mM NaCl) are quickly mixed at a ratio of 5 nmoles RPR209120 per microgram of DNA to produce a stable colloid of lipid/DNA/PEG complex particles.

The colloidal suspension of lipid complex is diluted in 100mM HEPES buffer (pH 7.5), and then reacted with a freshly made aqueous solution of acetic acid N-hydroxysulfosuccinimide ester (NHS-acetate) at room temperature for one hour. The

amount of NHS-acetate is five times molar ratio to cationic lipid. Particles are then concentrated by placing PEG 20,000 on top of a dialysis bag. When a final concentration of 0.8 to 1.0 mg DNA/ml is obtained the final product is subsequently dialyzed over night at 4°C against 5% dextrose, 20 mM NaCl.

5 Balb-C mice bearing M109 subcutaneous tumors are injected intravenously with increasing amounts of modified particles (corresponding to 100, 200, 400 and 800µg DNA). Twenty-four hours after injection, mice are sacrificed, main organs are collected, homogenized and the amount of CAT transgene is determined using a standard CAT Elisa (Roche, IN).

10 Figure 14 shows that lung, liver, kidney, heart, spleen and tumor express the CAT transgene.

EXAMPLE 6: CHARACTERIZATION OF MODIFIED PARTICLES

15 Particles are formed and modified as described in Example 5. Lipids are then extracted with 25 mM Hepes pH 8.5, 3M NaCl, 1% octylglucoside, dried and analyzed by HPLC with a C4 column using a gradient from 40 to 70% acetonitrile in water in 30 minutes (water and acetonitrile both contain 1% TFA). In these conditions, unmodified RPR209120 has an elution time of 14.8 minutes. Lipid extracted from particles treated with NHS-acetate
20 has an elution time of 19.5 minutes, demonstrating it has been chemically modified by the procedure.

 Having thus described a few particular embodiments of the invention, various alterations, modifications, and improvements will readily occur to those skilled in the art. Such alterations, modifications and improvements as are made obvious by this disclosure are
25 intended to be part of this description though not expressly stated herein, and are intended to be within the spirit and scope of the invention. The foregoing description is by way of example only, and not limiting. The invention is limited only as defined in the following claims and equivalents thereto.

Claims

1. A process for making neutral or anionic complexes containing sequestered DNA for gene transfer, comprising :
 - 5 forming a stable colloid comprising an aqueous phase having suspended therein a first DNA complex with a cationic surface potential comprising a DNA sequence complexed with a cationic lipid or polymer; and
modifying the surface potential of said first DNA complex to form a stable colloid comprising a second DNA complex with a neutral or net anionic surface potential.
- 10 2. The process of claim 1, wherein the surface potential of said first DNA complex is modified by adding a poly(alkylene oxide) to the aqueous phase of said colloid.
3. The process of claim 2, wherein said poly(alkylene oxide) is polyethylene glycol.
- 15 4. The process of claim 1, wherein the surface potential of said first DNA complex is modified by the covalent attachment of poly(alkylene oxides) to the cationic lipid or polymer.
- 20 5. The process of claim 4, wherein said poly(alkylene oxide) is polyethylene glycol.
6. The process of claim 1, wherein said first DNA complex is a complex of a DNA sequence with a cationic lipid or polymer comprising one or more cationic head groups, and said first DNA complex is modified by reacting said cationic head groups with a reagent that
25 reacts with the cationic head group to neutralize the positive charge thereon.

7. The process of claim 6, wherein said cationic lipid or polymer is selected from the group consisting of linear polyamines, branched polyamines and polyamines comprising guanidinium groups.
- 5 8. The process of claim 6, wherein said reagent is citraconic anhydride or N-hydroxysuccinimide acetate.
9. The process of claim 6, wherein reagent is an N-hydroxysuccinimide ester of a targeting ligand, so that a targeting ligand is covalently attached to said cationic lipid or polymer that
10 also modifies the surface potential of said first DNA complex.
10. The process of claim 9, wherein said targeting ligand is an amino sugar or peptide.
11. The process of claim 1, wherein said first DNA complex further comprises a targeting
15 ligand covalently attached to said cationic lipid or polymer.
12. The process of claim 4, wherein said poly(alkylene oxide) is only covalently attached to cationic lipids or polymers on the surface of said first DNA complex.
- 20 13. The process of claim 4, wherein said poly(alkylene oxide) is covalently attached to cationic lipids or polymers on the surface of and in the interior of said first DNA complex.
14. The process of claim 6, wherein said reagent is only reacted with cationic head groups of cationic lipids or polymers on the surface of said first DNA complex.
- 25 15. The process of claim 6, wherein said reagent is reacted with cationic head groups of cationic lipids or polymers on the surface of and in the interior of said first DNA complex.

16. A stable colloid comprising an aqueous phase having suspended therein a first DNA complex with a cationic surface potential comprising an exogenous therapeutic DNA sequence for delivery in vivo to a patient in need thereof, complexed with a cationic lipid or
5 polymer, wherein said aqueous phase comprises an aqueous solution of a poly(alkylene oxide).

17. A stable colloid comprising an aqueous phase having suspended therein a first DNA complex with a cationic surface potential comprising an exogenous therapeutic DNA
10 sequence for delivery in vivo to a patient in need thereof, complexed with a cationic lipid or polymer, wherein said surface potential of said first DNA complex is modified by the covalent attachment of poly(alkylene oxides) to the cationic lipid or polymer.

18. A stable colloid comprising an aqueous phase having suspended therein a first DNA
15 complex with a cationic surface potential comprising an exogenous therapeutic DNA sequence for delivery in vivo to a patient in need thereof, complexed with a cationic lipid or polymer comprising one or more cationic head groups modified by reaction with a reagent that neutralizes the positive charge thereon.

20 19. Use of a colloid of claim 16, 17 or 18 to for the preparation of a medicament comprising an exogenous therapeutic DNA sequence for treating by gene therapy a patient in need thereof.

20. Use of a colloid of claim 16, 17 or 18 to for the preparation of a medicament intended
25 for the administration of an exogenous therapeutic DNA sequence.




Figure 1




Figure 2




Figure 3




Figure 4




Figure 5

6/13




Figure 6




Figure 7

8/13




Figure 8

9/13




Figure 9




Figure 10

1/13




Figure 11




Figure 12

12/13





Figure 13

Figure 14



(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
6 June 2002 (06.06.2002)

PCT

(10) International Publication Number
WO 02/043769 A3

(51) International Patent Classification⁷: **A61K 47/48**

(21) International Application Number: **PCT/EP01/13800**

(22) International Filing Date:
27 November 2001 (27.11.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/253,827 29 November 2000 (29.11.2000) US
0105346.1 5 March 2001 (05.03.2001) GB

(71) Applicant (for all designated States except US): **GEN-CELL S.A.** [FR/FR]; 72-82, rue Léon Geffroy, F-94400 Vitry-sur-Seine (FR).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **HOFLAND, Hans** [NL/US]; 126 Albacore Lane, Foster City, CA 94404 (US). **LAMONS, Donald** [US/US]; 125 Fox Crossing Court, Emerald Hills, CA 94062 (US). **MENG, Xiao-Ying** [CN/US]; 5317 Shamrock CM, Fremont, CA 94555 (US).

(74) Agent: **LECCA, Patricia**; Gencell S.A., 72-82, rue Léon Geffroy, F-94400 Vitry-sur-Seine (FR).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BI, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:
9 October 2003

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 02/043769 A3

(54) Title: **NEUTRAL AND ANIONIC COLLOIDAL PARTICLES FOR GENE DELIVERY**

(57) Abstract: Processes for making neutral or anionic complexes containing sequestered DNA for gene transfer, by forming a stable colloid containing an aqueous phase having suspended therein a first DNA complex with a cationic surface potential comprising a DNA sequence complexed with a cationic lipid or polymer, and modifying the surface potential of the first DNA complex to form a stable colloid comprising a second DNA complex with a neutral or net anionic surface potential.

INTERNATIONAL SEARCH REPORT

Internat Application No

PCT/EP 01/13800

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K47/48

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EMBASE, BIOSIS, EPO-Internal, CHEM ABS Data, MEDLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	FINSINGER D ET AL: "PROTECTIVE COPOLYMERS FOR NONVIRAL GENE VECTORS: SYNTHESIS, VECTOR CHARACTERIZATION AND APPLICATION IN GENE DELIVERY" GENE THERAPY, MACMILLAN PRESS LTD., BASINGSTOKE, GB, vol. 7, no. 14, July 2000 (2000-07), pages 1183-1192, XP001005915 ISSN: 0969-7128	1-20
Y	abstract; figure 1	1-20
X	WO 98 08489 A (BISCHOFF RAINER ;TRANSGENE SA (FR)) 5 March 1998 (1998-03-05) claims 1,2,7,9,15,16; table 2	1-20
	--- -/-- ---	



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *Z* document member of the same patent family

Date of the actual completion of the international search

7 February 2003

Date of mailing of the international search report

14/02/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Berte, M

INTERNATIONAL SEARCH REPORT

Internal Publication No
PCT/EP 01/13800

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>VERRECCHIA T ET AL: "Non-stealth (poly(lactic acid/albumin)) and stealth (poly(lactic acid-polyethylene glycol)) nanoparticles as injectable drug carriers" JOURNAL OF CONTROLLED RELEASE, ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM, NL, vol. 36, no. 1, 1 September 1995 (1995-09-01), pages 49-61, XP000525974 ISSN: 0168-3659 abstract</p>	1
Y	<p>FREDERIC M ET AL: "Introduction of cyclic guanidines into cationic lipids for non-viral gene delivery" TETRAHEDRON LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 41, no. 5, January 2000 (2000-01), pages 675-679, XP004187753 ISSN: 0040-4039 abstract</p>	1-20
Y	<p>WO 98 54130 A (DUBERTRET CATHERINE ;BYK GERARDO (FR); SCHERMAN DANIEL (FR); RHONE) 3 December 1998 (1998-12-03) page 9, line 5 -page 11, line 4; claims 1,19; examples 3-6 page 26, line 22 - line 25</p>	1-20
P,X	<p>PITARD B ET AL: "Sterically stabilized BGTC-based lipoplexes: structural features and gene transfection into the mouse airways in vivo." THE JOURNAL OF GENE MEDICINE. ENGLAND 2001 SEP-OCT, vol. 3, no. 5, September 2001 (2001-09), pages 478-487, XP008013418 ISSN: 1099-498X abstract</p>	1-20

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP 01/13800

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Present claims 1-20 relate to an extremely large number of possible products. In fact, the claims contain so many variables that a lack of clarity (and/or conciseness) within the meaning of Article 6 PCT arises to such an extent as to render a meaningful search of the claims impossible. Consequently, the search has been carried out for those parts of the application which do appear to be clear (and/or concise), namely products have been searched recited in the examples and closely related homologous products mentioned in the description.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Internal Application No

PCT/EP 01/13800

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9808489	A	05-03-1998	AU 729077 B2	25-01-2001
			AU 3781597 A	19-03-1998
			EP 0941066 A1	15-09-1999
			WO 9808489 A1	05-03-1998
			JP 2000516948 T	19-12-2000
			US 6271208 B1	07-08-2001
WO 9854130	A	03-12-1998	FR 2763943 A1	04-12-1998
			AU 738320 B2	13-09-2001
			AU 8022198 A	30-12-1998
			BR 9809506 A	20-06-2000
			CN 1257480 T	21-06-2000
			EP 0984925 A1	15-03-2000
			WO 9854130 A1	03-12-1998
			HU 0001937 A2	28-10-2000
			JP 2002502388 T	22-01-2002
			NO 995808 A	26-11-1999
			PL 336983 A1	31-07-2000
			US 6300321 B1	09-10-2001
			ZA 9804440 A	10-12-1998